X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-12-04 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $5.96 | +8,389 | 81,794 | +11% | +$49,998 | ||||||
2025-12-02 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $4.37 | -220,000 | 6,869,863 | -3% | -$961,400 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.15 | -713 | 68,777 | -1% | -$1,535 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | O'Neill Gilmore Neil | CEO | S - Sale | $2.15 | -5,603 | 269,087 | -2% | -$12,064 | ||||||
2025-12-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.15 | -461 | 15,908 | -3% | -$993 | ||||||
2025-12-02 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $11.13 | -10,000 | 333,576 | -3% | -$111,300 | ||||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Howton David T | COO | S - Sale+OE | $5.11 | -4,932 | 32,908 | -13% | -$25,203 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Pres, CEO | S - Sale+OE | $5.11 | -10,808 | 81,388 | -12% | -$55,229 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Chief Regulatory Officer | S - Sale+OE | $5.11 | -4,483 | 26,660 | -14% | -$22,908 | |||||
| D | 2025-12-03 | SLDB | Solid Biosciences Inc. | Herzich Paul | CTO | S - Sale+OE | $5.11 | -2,701 | 26,622 | -9% | -$13,802 | |||||
| D | 2025-12-03 | NBIX | Neurocrine Biosciences Inc | Lyons Gary A | Dir | S - Sale+OE | $152.61 | -15,000 | 120,482 | -11% | -$2,289,083 | |||||
| D | 2025-12-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Chief Medical Officer | S - Sale+OE | $39.14 | -1,652 | 66,562 | -2% | -$64,659 | |||||
| M | 2025-12-02 | VCEL | Vericel Corp | Wotton Paul K | Dir | S - Sale | $37.90 | -5,000 | 25,602 | -16% | -$189,500 | |||||
| M | 2025-12-01 | ADVM | Adverum Biotechnologies, Inc. | Leonard Braden Michael | 10% | S - Sale | $4.19 | -574,886 | 2,620,440 | -18% | -$2,407,833 | |||||
2025-12-03 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $1.12 | -8,056 | 127,735 | -6% | -$9,019 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.12 | -104,347 | 6,350,415 | -2% | -$116,827 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $1.12 | -41,687 | 501,652 | -8% | -$46,673 | ||||||
2025-12-03 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Chief Bus Ofcr, Interim CFO | S - Sale | $1.12 | -37,261 | 374,309 | -9% | -$41,717 | ||||||
| DM | 2025-12-01 | BCRX | Biocryst Pharmaceuticals Inc | Barnes Alane P | GC | S - Sale+OE | $7.21 | -161,680 | 345,476 | -32% | -$1,164,967 | |||||
2025-12-01 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Dir | S - Sale | $23.25 | -22,249 | 85,852 | -21% | -$517,189 | ||||||
2025-12-01 | IMVT | Immunovant, Inc. | Hughes Douglas J. | Dir | S - Sale | $23.24 | -15,000 | 120,773 | -11% | -$348,665 | ||||||
2025-12-01 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $5.98 | -191,854 | 13,728,924 | -1% | -$1,147,786 | ||||||
| M | 2025-12-01 | ELUT | Elutia Inc. | Ferguson Matthew | CFO | P - Purchase | $0.66 | +10,000 | 379,071 | +3% | +$6,610 | |||||
2025-11-13 | SRZN | Surrozen, Inc./De | Kutzkey Tim | Dir, 10% | P - Purchase | $12.65 | +315,457 | 2,160,027 | +17% | +$3,990,531 | ||||||
2025-12-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $6.00 | -22,000 | 1,188,391 | -2% | -$132,070 | ||||||
| D | 2025-11-28 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale+OE | $19.50 | -162,820 | 216,637 | -43% | -$3,174,990 | |||||
2025-11-28 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $9.00 | +2,777 | 577,872 | 0% | +$24,993 | ||||||
| D | 2025-11-28 | NBIX | Neurocrine Biosciences Inc | Benevich Eric | Chief Commercial Officer | S - Sale+OE | $151.74 | -5,970 | 44,893 | -12% | -$905,881 | |||||
| DM | 2025-11-28 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $4.58 | -370,172 | 1,006,439 | -27% | -$1,695,906 | |||||
2025-12-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $71.60 | -829 | 42,123 | -2% | -$59,356 | ||||||
2025-09-05 | MGX | Metagenomi, Inc. | Thomas Brian C. | Dir | S - Sale | $1.81 | -2,701 | 2,514,790 | 0% | -$4,889 | ||||||
2025-09-05 | MGX | Metagenomi, Inc. | Wapnick Pamela | CFO | S - Sale | $1.81 | -1,576 | 190,532 | -1% | -$2,853 | ||||||
| D | 2025-12-01 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $68.92 | -16,569 | 708,719 | -2% | -$1,141,925 | |||||
| D | 2025-09-05 | MGX | Metagenomi, Inc. | Irish Jian | CEO | S - Sale+OE | $1.81 | -1,602 | 565,441 | 0% | -$2,900 | |||||
| M | 2025-11-26 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $19.10 | -160,734 | 2,709,241 | -6% | -$3,070,747 | |||||
2025-09-05 | MGX | Metagenomi, Inc. | Wein Matthew | See Remarks | S - Sale | $1.81 | -199 | 115,230 | 0% | -$360 | ||||||
| D | 2025-11-28 | GILD | Gilead Sciences, Inc. | Bluestone Jeffrey | Dir | S - Sale+OE | $125.08 | -5,000 | 8,920 | -36% | -$625,400 | |||||
| DM | 2025-11-26 | GILD | Gilead Sciences, Inc. | Kramer Kelly A. | Dir | S - Sale+OE | $127.11 | -5,611 | 1,339 | -81% | -$713,186 | |||||
2025-11-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $126.54 | -10,000 | 571,203 | -2% | -$1,265,444 | ||||||
| M | 2025-11-26 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.41 | -189,431 | 13,920,778 | -1% | -$1,213,667 | |||||
| DM | 2025-11-26 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $40.12 | -74,925 | 0 | -100% | -$3,005,825 | |||||
| D | 2025-11-28 | DVLT | Datavault Ai Inc. | Scilex Holding Co | 10% | S - Sale+OE | $2.06 | -422,299 | 265,102,560 | 0% | -$871,161 | |||||
2025-11-25 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | CFO | S - Sale | $70.00 | -1,500 | 196,371 | -1% | -$105,000 | ||||||
2025-11-24 | ELUT | Elutia Inc. | Mills C Randal | Pres, CEO | P - Purchase | $0.60 | +5,000 | 358,785 | +1% | +$3,000 | ||||||
| M | 2025-11-24 | VIR | Vir Biotechnology, Inc. | Svf Endurance (Cayman) Ltd | 10% | S - Sale | $6.27 | -463,774 | 14,110,209 | -3% | -$2,906,278 | |||||
2025-11-25 | RGEN | Repligen Corp | Loeillot Olivier | CEO | S - Sale | $170.00 | -7,041 | 35,898 | -16% | -$1,196,970 | ||||||
| D | 2025-11-25 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $74.00 | -5,418 | 110,994 | -5% | -$400,932 | |||||
| D | 2025-11-25 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $75.08 | -66,000 | 885,337 | -7% | -$4,954,962 | |||||
| DM | 2025-11-24 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $40.03 | -18,120 | 0 | -100% | -$725,341 | |||||
2025-11-25 | EXEL | Exelixis, Inc. | Johnson David Edward | Dir | P - Purchase | $43.12 | +27,532 | 1,571,438 | +2% | +$1,187,235 | ||||||
2025-11-25 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Dir | S - Sale | $28.03 | -10,000 | 124,573 | -7% | -$280,281 | ||||||
2025-11-24 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Chief Scientific Officer | S - Sale | $12.30 | -4,000 | 138,004 | -3% | -$49,200 | ||||||
| DM | 2025-11-20 | DBVT | Dbv Technologies S.A. | Mohideen Pharis | Chief Medical Officer | S - Sale+OE | $2.86 | -8,120 | 145,529 | -5% | -$23,207 | |||||
2025-11-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $26.50 | -757 | 145,402 | -1% | -$20,063 | ||||||
2025-11-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $26.50 | -1,776 | 332,883 | -1% | -$47,070 | ||||||
2025-11-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $26.50 | -598 | 167,789 | 0% | -$15,849 | ||||||
2025-11-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $26.50 | -887 | 142,769 | -1% | -$23,509 | ||||||
| D | 2025-11-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $26.50 | -2,663 | 878,173 | 0% | -$70,579 | |||||
| M | 2025-11-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $28.23 | -1,051 | 66,143 | -2% | -$29,669 | |||||
| DM | 2025-11-20 | ADPT | Adaptive Biotechnologies Corp | Benzeno Sharon | Chief Commercial Ofc Imm Med | S - Sale+OE | $16.73 | -606,402 | 296,791 | -67% | -$10,144,026 | |||||
| M | 2025-11-20 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $42.18 | -72,230 | 374,029 | -16% | -$3,046,928 | |||||
2025-11-20 | IPSC | Century Therapeutics, Inc. | Cowan Chad | Chief Scientific Officer | S - Sale | $0.50 | -5,462 | 997,724 | -1% | -$2,736 | ||||||
2025-11-21 | IKT | Inhibikase Therapeutics, Inc. | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 10% | P - Purchase | $1.45 | +2,068,965 | 13,018,965 | +19% | +$2,999,999 | ||||||
| D | 2025-11-19 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.00 | -21,000 | 3,738,233 | -1% | -$336,000 | |||||
| D | 2025-11-20 | AMGN | Amgen Inc | Grygiel Nancy A. | SVP, CCO | S - Sale+OE | $337.26 | -3,139 | 7,330 | -30% | -$1,058,667 | |||||
2025-11-20 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $23.62 | -12,626 | 173,511 | -7% | -$298,237 | ||||||
2025-11-17 | VXRT | Vaxart, Inc. | Heron Elaine J | Dir | P - Purchase | $0.40 | +40,000 | 96,566 | +71% | +$15,921 | ||||||
2025-11-19 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | P - Purchase | $0.50 | +35,000 | 3,271,453 | +1% | +$17,329 | ||||||
2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $9.27 | -1,127 | 240,991 | 0% | -$10,447 | ||||||
2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $9.27 | -615 | 72,646 | -1% | -$5,701 | ||||||
2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $9.27 | -386 | 65,476 | -1% | -$3,578 | ||||||
2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $9.27 | -549 | 68,381 | -1% | -$5,089 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Chief Technical Officer | S - Sale | $9.27 | -721 | 63,476 | -1% | -$6,684 | ||||||
| D | 2025-11-18 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale+OE | $70.38 | -20,000 | 958,761 | -2% | -$1,407,586 | |||||
| D | 2025-11-18 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale+OE | $70.14 | -13,388 | 50,425 | -21% | -$939,008 | |||||
2025-11-19 | IVVD | Invivyd, Inc. | McLaughlin Kevin F | Dir | P - Purchase | $2.50 | +50,000 | 50,000 | New | +$125,000 | ||||||
2025-11-18 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $8.79 | -19,341 | 3,744,741 | -1% | -$170,048 | ||||||
2025-11-18 | TWST | Twist Bioscience Corp | Johannessen Jan | Dir | S - Sale | $24.77 | -7,044 | 14,859 | -32% | -$174,480 | ||||||
| D | 2025-04-28 | PLUR | Pluri Inc. | Manieu Alexandre Weinstein | Dir, 10% | P - Purchase | $4.61 | +452,702 | 2,396,367 | +23% | +$2,086,956 | |||||
| D | 2025-11-17 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale+OE | $10.59 | -1,635 | 3,594 | -31% | -$17,315 | |||||
| D | 2025-11-19 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.16 | -40,000 | 913,839 | -4% | -$166,400 | |||||
| D | 2025-11-17 | LENZ | Lenz Therapeutics, Inc. | Olsson Shawn | Chief Commercial Officer | S - Sale+OE | $26.10 | -10,000 | 4,733 | -68% | -$261,022 | |||||
2025-11-17 | ELUT | Elutia Inc. | Colpman David | Dir | P - Purchase | $0.74 | +15,500 | 18,598 | +500% | +$11,470 | ||||||
2025-11-17 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $13.19 | -2,915 | 64,974 | -4% | -$38,437 | ||||||
2025-11-17 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $13.19 | -1,804 | 33,454 | -5% | -$23,788 | ||||||
2025-11-18 | PLX | Protalix Biotherapeutics, Inc. | Bar-Shalev Amos | Dir | S - Sale | $1.87 | -168 | 7,500 | -2% | -$314 | ||||||
2025-11-17 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $9.10 | -5,208 | 123,088 | -4% | -$47,393 | ||||||
2025-11-17 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $9.10 | -7,248 | 139,685 | -5% | -$65,957 | ||||||
2025-11-18 | RGEN | Repligen Corp | Bylund James | COO | S - Sale | $151.21 | -2,191 | 21,520 | -9% | -$331,301 | ||||||
2025-11-17 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.45 | -32,456 | 3,236,453 | -1% | -$14,735 | ||||||
2025-11-17 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | SVP, Chief Technical Officer | S - Sale | $1.22 | -786 | 217,721 | 0% | -$959 | ||||||
2025-11-17 | VIVS | Vivosim Labs, Inc. | Gobel David | Dir | S - Sale | $2.24 | -3,266 | 0 | -100% | -$7,300 | ||||||
2025-11-17 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $14.05 | -238 | 269,343 | 0% | -$3,344 | ||||||
2025-11-17 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $125.23 | -2,500 | 154,555 | -2% | -$313,075 | ||||||
| D | 2025-11-17 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $125.86 | -28,000 | 107,193 | -21% | -$3,524,173 | |||||
| D | 2025-11-17 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $41.43 | -1,000 | 0 | -100% | -$41,430 | |||||
2025-11-17 | VIR | Vir Biotechnology, Inc. | O'Byrne Jason | EVP, CFO | S - Sale | $5.56 | -6,799 | 110,701 | -6% | -$37,782 | ||||||
| M | 2025-11-14 | FENC | Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 10% | S - Sale | $8.27 | -246,018 | 3,764,082 | -6% | -$2,035,625 | |||||
2025-11-17 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $3.38 | -6,375 | 343,999 | -2% | -$21,522 | ||||||
2025-11-17 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $1.33 | -1,367 | 93,971 | -1% | -$1,818 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |